Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd (NQ: ROIV )

11.00 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2
Open 11.00
Bid (Size) 11.00 (12)
Ask (Size) 11.41 (10)
Prev. Close 11.00
Today's Range 11.00 - 11.00
52wk Range 8.245 - 13.24
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Evaluating Roivant Sciences: Insights From 6 Financial Analysts
Via Benzinga
The Analyst Verdict: Roivant Sciences In The Eyes Of 6 Experts
Via Benzinga

Performance

YTD
-3.08%
-3.08%
1 Month
+2.90%
+2.90%
3 Month
+3.77%
+3.77%
6 Month
+6.28%
+6.28%
1 Year
+2.52%
+2.52%

More News

Read More
ROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024
Via InvestorPlace
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Vivek Ramaswamy Breathes New Life Into Beaten Down BuzzFeed Stock: What's Going On?
Via Benzinga
Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know
Via Benzinga
Where Roivant Sciences Stands With Analysts
Via Benzinga
The Analyst Landscape: 4 Takes On Roivant Sciences
Via Benzinga
Roivant Sciences Earnings Preview
Via Benzinga
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
From Roivant Sciences
Via GlobeNewswire
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Via InvestorPlace
3 Healthcare Stocks With the Potential to Triple Your Investment by 2026
Via InvestorPlace
Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study
Via Benzinga
Assessing Roivant Sciences: Insights From 5 Financial Analysts
Via Benzinga
Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study
Via Investor's Business Daily
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
From Roivant Sciences
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Solar Stocks Rally, Led By Sunrun, SolarEdge, Enphase
Via Investor's Business Daily
5 Value Stocks In The Healthcare Sector
Via Benzinga
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
From Roivant Sciences
Via GlobeNewswire
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
Via Investor's Business Daily
Earnings Scheduled For February 13, 2024
Via Benzinga
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
Via Benzinga
Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.